Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform: 'Top Pick' at Citizens

January 15, 2026 4:16 AM EST Send to a Friend
Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $140.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login